U.S. patent number 5,753,270 [Application Number 08/576,170] was granted by the patent office on 1998-05-19 for topical treatment of diseased skin disorders.
This patent grant is currently assigned to Patrick A. Beauchamp, James A. Rogers. Invention is credited to Patrick A. Beauchamp, James A. Rogers.
United States Patent |
5,753,270 |
Beauchamp , et al. |
May 19, 1998 |
Topical treatment of diseased skin disorders
Abstract
A preparation which is compatible with the skin for the
treatment of labial disease and acne. The preparation comprises a
mixture of: (a) at least one compound selected from an antiseptic
compound and an anesthetic compound which is: (i) a terpene, (ii) a
phenolic compound, or (iii) an alcohol; (b) a quaternary ammonium
antiseptic compound; (c) an antiseptic compound selected from
compounds containing iodine, salts thereof and complexes thereof
dissolved in an organic skin penetrating solvent, wherein said
solvent comprises acetone.
Inventors: |
Beauchamp; Patrick A. (Calgary,
Alberta, CA), Rogers; James A. (Edmonton, Alberta,
CA) |
Assignee: |
Beauchamp; Patrick A.
(Edmonton, CA)
Rogers; James A. (Edmonton, CA)
|
Family
ID: |
4136452 |
Appl.
No.: |
08/576,170 |
Filed: |
December 21, 1995 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
108167 |
Aug 18, 1993 |
|
|
|
|
715710 |
Jun 18, 1991 |
|
|
|
|
476141 |
Feb 7, 1990 |
|
|
|
|
242121 |
Sep 9, 1988 |
|
|
|
|
Foreign Application Priority Data
Current U.S.
Class: |
424/667; 514/556;
514/724; 514/728 |
Current CPC
Class: |
A61P
17/00 (20180101); A61K 33/18 (20130101); A61K
33/18 (20130101); A61K 31/045 (20130101); A61K
31/335 (20130101); A61K 31/05 (20130101); A61K
31/14 (20130101); A61K 33/18 (20130101); A61K
2300/00 (20130101); A61K 33/18 (20130101); A61K
31/045 (20130101); A61K 31/05 (20130101) |
Current International
Class: |
A61K
33/18 (20060101); A61K 033/36 () |
Field of
Search: |
;424/667
;514/556,724,728 |
References Cited
[Referenced By]
U.S. Patent Documents
|
|
|
54763 |
January 1866 |
Bourdil |
608612 |
August 1898 |
Klever |
4294852 |
October 1981 |
Wildnauer et al. |
|
Primary Examiner: Fay; Zohreh
Attorney, Agent or Firm: Hughes; Ivor M. Hughes; Neil H.
Sarkis; Marcelo K.
Parent Case Text
This application is a continuation of U.S. application Ser. No.
08/108,167, filed Aug. 18, 1993, now abandoned, which is a
continuation application of U.S. application Ser. No. 07/715,710,
filed Jun. 18, 1991, now abandoned, which is a continuation
application of U.S. application Ser. No. 07/476,141, filed Feb. 7,
1990, now abandoned, which is a continuation application of U.S.
application Ser. No. 07/242,121, filed Sep. 9, 1988, now abandoned.
Claims
The embodiments of the invention in which an exclusive property or
privilege is claimed are as follow:
1. A preparation which is compatible with the skin for the
treatment of labial disease and acne, the preparation comprising a
mixture of:
(a) at least one compound selected from an antiseptic compound and
an anesthetic compound which is:
(i) a terpene,
(ii) a phenolic compound, or
(iii) an alcohol;
(b) a quaternary ammonium antiseptic compound;
(c) an antiseptic compound selected from compounds containing
iodine, salts thereof and complexes thereof dissolved in an organic
skin penetrating solvent, wherein said solvent comprises
acetone.
2. The preparation of claim 1 wherein the terpene is an oxygenated
terpene.
3. The preparation of claim 1 or 2 wherein the quaternary ammonium
antiseptic compound is benzethonium chloride.
4. The preparation of claim 1 wherein the antiseptic an/or
anesthetic compound is a phenolic compound and the phenolic
compound is thymol.
5. The preparation of claim 2 wherein the oxygenated terpene is
selected from eucalyptol and methol and mixtures thereof.
6. The preparation of claim 1 wherein the at least one compound
selected from an antiseptic compound and an anesthetic compound
comprises a mixture of at least one phenolic compound and at least
one terpene.
7. The preparation of claim 6 wherein the at least one phenolic
compound and at least one terpene comprises eucalyptol, menthol and
thymol.
8. The preparation of claim 7 wherein the quaternary ammonium
antiseptic compound is benzethonium chloride.
9. The preparation of claim 8 wherein the antiseptic compound
containing iodine, its salts or complexes comprises iodine and
potassium iodid.
10. The preparation of claim 9 wherein the organic skin penetrating
solvent further comprises water.
11. A preparation for the treatment of the labia and acne
comprising a mixture of menthol, thymol, eucalyptol, potassium
iodide, iodine, and benzethonium chloride in a solution of acetone
and water.
12. A preparation according to claim 11 formulated as a galenical
form, selected from a gel, cream, lotion, ointment, or paste.
13. A method of treating labial diseases and acne comprising
administering a preparation compatible with the skin for the
treatment of labial diseases and acne, the preparation comprising a
mixture of:
(a) at least one compound selected from an antiseptic compound and
an anesthetic compound which is;
(i) a terpene,
(ii) a phenolic compound, or
(iii) an alcohol;
(b) a quaternary ammonium antiseptic compound;
(c) an antiseptic compound selected from compounds containing
iodine, salts thereof and complexes thereof dissolved in an organic
skin penetrating solvent, wherein said solvent comprises
acetone.
14. The method of claim 13 wherein the terpene is an oxygenated
terpene.
15. The method of claim 13 or 14 wherein the quaternary ammonium
antiseptic compound is benzethonium chloride.
16. The method of claim 13 wherein the compound selected from an
antiseptic compound and an anesthetic compound is a phenolic
compound and the phenolic compound is thymol.
17. The method of claim 14 wherein the oxygenated terpene is
selected from eucalyptol and methol and mixtures thereof.
18. The method of claim 13 wherein the at least one compound
selected from an antiseptic compound and an anesthetic compound
comprises a mixture of at least one phenolic compound and at least
one terpene.
19. The method of claim 18 wherein the at least one phenolic
compound and at least one terpene comprises eucalyptol, menthol and
thymol.
20. The method of claim 19 wherein the quaternary ammonium
antiseptic compound is benzethonium chloride.
21. The method of claim 20 wherein the antiseptic compound
containing iodine, its salts or complexes comprises iodine and
potassium iodide.
22. The method of claim 21 wherein the organic skin penetrating
solvent further comprises water.
23. The preparation of claim 1 wherein the at least one compound
selected from an antiseptic compound and an anesthetic compound
comprises eugenol, camphor, hexetidine or anethol.
24. The preparation of claim 1 wherein the organic skin penetrating
solvent may comprise dimethyl sulfoxide (DMS), azone, propylene
glycol, dimethyl formamide, dimethyl acetamide, ethyl alcohol,
isopropyl alcohol or the like in water.
25. The preparation of claim 1 wherein the quaternary ammonium
antiseptic compound comprises a benzalkonium chloride, cetyl
trimethylammonium bromide (CTAB) and cetyl pyridium chloride or the
like.
26. The method of claim 13 wherein the at least one compound
selected from an antiseptic compound and an anesthetic compound
comprises eugenol, camphor, hexetidine or anethol or the like.
27. The method of claim 13 wherein the organic skin penetrating
solvent may comprise dimethyl sulfoxide (DMSO), azone, propylene
glycol, dimethyl formamide, dimethyl acetamide, ethyl alcohol,
isopropyl alcohol or the like in water.
28. The method of claim 13 wherein the quaternary ammonium
antiseptic compound may be a benzolkonium chloride, cetyl
trimethylammonium bromide (CTGAB) and cetyl pyridium chloride or
the like.
29. The preparation of claim 1 or 2 wherein
(a) the at least one compound selected from an antiseptic compound
and an anesthetic compound is in a range of about 0.02%--about 2%
by weight of the preparation;
(b) the quaternary ammonium antiseptic compound is in the range of
about 0.05%--about 3% by weight of the preparation;
(c) the antiseptic compound containing iodine, salts thereof and
complexes are in the range of about 0.02%--about 2% by weight in
preparation.
30. The preparation of claim 1 or 2 wherein the organic skin
penetrating solvent may be in the range exceeding about 50%.
31. The preparation of claim 4, 5, or 6 wherein
(a) the at least one compound selected from an antiseptic compound
and an anesthetic compound is in a range of about 0.02%--about 2%
by weight of the preparation;
(b) the quaternary ammonium antiseptic compound is in the range of
about 0.05%--about 3% by weight of the preparation;
(c) the antiseptic compound containing iodine, salts thereof and
complexes are in the range of about 0.02%--about 2% by weight in
preparation.
32. The preparation of claim 8, 9, or 10 wherein
(a) the at least one compound selected from an antiseptic compound
and an anesthetic compound is in a range of about 0.02%--about 2%
by weight of the preparation;
(b) the quaternary ammonium antiseptic compound is in the range of
about 0.05%--about 3% by weight of the preparation;
(c) the antiseptic compound containing iodine, salts thereof and
complexes are in the range of about 0.02%--about 2% by weight in
preparation.
33. The preparation of claim 10, 24, or 27 wherein the organic skin
penetrating solvent exceeds about 50%.
34. The method of claim 13 or 14 wherein
(a) the at least one compound selected from an antiseptic compound
and an anesthetic compound is in a range of about 0.02%--about 2%
by weight of the preparation;
(b) the quaternary ammonium antiseptic compound is in the range of
about 0.05%--about 3% by weight of the preparation;
(c) the antiseptic compound containing iodine, salts thereof and
complexes are in the range of about 0.02%--about 2% by weight in
preparation.
35. The method of claim 14, 15, or 16 wherein (a) the at least one
compound selected from an antiseptic compound and an anesthetic
compound is in a range of about 0.02%--about 2% by weight of the
preparation;
(b) the quaternary ammonium antiseptic compound is in the range of
about 0.05%--about 3% by weight of the preparation;
(c) the antiseptic compound containing iodine, salts thereof and
complexes are in the range of about 0.02%--about 2% by weight in
preparation.
36. The method of claim 17, 18, or 19 wherein
(a) the at least one compound selected from an antiseptic compound
and an anesthetic compound is in a range of about 0.02%--about 2%
by weight of the preparation;
(b) the quaternary ammonium antiseptic compound is in the range of
about 0.05%--about 3% by weight of the preparation;
(c) the antiseptic compound containing iodine, salts thereof and
complexes are in the range of about 0.02%--about 2% by weight in
preparation.
37. The method of claim 20, 21, or 25 wherein
(a) the at least one compound selected from an antiseptic compound
and an anesthetic compound is in a range of about 0.02%--about 2%
by weight of the preparation;
(b) the quaternary ammonium antiseptic compound is in the range of
about 0.05%--about 3% by weight of the preparation;
(c) the antiseptic compound containing iodine, salts thereof and
complexes are in the range of about 0.02%--about 2% by weight in
preparation.
38. The method of claim 27 wherein
(a) the at least one compound selected from an antiseptic compound
and an anesthetic compound is in a range of about 0.02%--about 2%
by weight of the preparation;
(b) the quaternary ammonium antiseptic compound is in the range of
about 0.05%--about 3% by weight of the preparation;
(c) the antiseptic compound containing iodine, salts thereof and
complexes are in the range of about 0.02%--about 2% by weight in
preparation.
39. The method of claim 26 wherein the organic skin penetrating
solvent may be in the range exceeding about 50%.
40. The preparation of claim 11 or 12 wherein said mixture
comprises:
about 1.67% by weight of Menthol,
about 0.34% by weight of Thymol,
about 0.04% by weight of Eucalyptol,
about 0.04% by weight of Iodine,
about 0.04% by weight of Potassium lodid,
about 0.66% by volume of Benzethronium Chloride,
about 65% by volume of Acetone, and
about 23.4% by volume of Water.
41. The preparation of claims 9 or 12 wherein said mixture
comprises:
about 0.9% by weight of Menthol,
about 0.34% by weight of Thymol,
about 0.13% by weight of Benzethonium Cl,
about 0.12% by weight of K Iodide,
about 0.12% by weight of Iodine,
about 0.04% by weight of Eucalyptus Oil
about 8.0% by weight of Glycerine,
about 0.75% by weight of Natrosol,
about 0.04% by weight of Lavender Oil,
about 44% by volume of Water,
about 45% by volume of Acetone.
Description
FIELD OF INVENTION
The present invention relates to a preparation of medicinal agents
having a synergistic effect which has medical value in the topical
treatment of a variety of diseased skin disorders including Herpes
Simplex, acne, psoriasis, and dermatitis.
BACKGROUND OF THE INVENTION
Herpes Simplex infections described as Herpes labialis and Herpes
nasalis are commonly known as cold sores and fever blisters. They
cause painful itching and burning and great discomfort to those
inflicted by them. Herpes genitalis is manifested by cycles of
emerging skin lesions and eruptions which are also discomforting
and lead to considerable levels of anxiety. As a venereal disease
it has become more prevalent than syphilis or gonorrhea. Although
many creams and ointments have been available over the years as
medications, few have shown any significant levels of
effectiveness. Acne vulgaris is a common disease, particularly
among adolescents, which has as the characteristic lesions the open
comedo (blackhead) and closed comedo. Although many have only mild
acne some experience severe forms of acne and may lead to extensive
scarring. Even the milder forms can cause considerable
psychological distress for the individual. Psoriasis is a chronic
disease characterized by epidermal hyperplasia and a greatly
accelerated rate of epidermal production. The lesions are
characteristically red, slightly raised and scaly. Instead of the
normal 28 days from cell division in the basal layers until the
cell is shed from the stratum corneum, in psoriasis it takes only 3
to 4 days for this to occur. The mechanism for this and the other
signs and symptoms of psoriasis are not presently understood.
Atopic dermatitis (eczema) is an allergic skin disease which is
characterized by circumscribed discrete wheals with erythematous
raised serpiginous borders and blanched centres and itching. Both
children and adults are affected by this disease which is chronic
and is further characterized by spontaneous exacerbations and
remissions. It may last for years but does not last forever.
There have been and still are numerous products available to treat
the symptoms of Herpes Simplex and acne. Many of these have
incorporated an antiviral agent into ointments, creams, and lotions
(U.K. patent 2 167 296 A, May 24, 1984). These have provided only
limited degrees of relief in most cases and usually require
frequent and continuous application. Many over-the-counter products
contain ingredients which supposedly provide symptomatic relief of
discomfort due to various skin conditions but none of which are
claimed to be effective against Herpes infections except the recent
drug, Acyclovir, which is claimed to have some topical activity.
Consequently, Herpes victims usually have to suffer through the
complete cycle of eruptions often leaving unpleasant skin
blemishes. In addition to the lack of effectiveness of most
products against lesions of Herpes infections, many do not
satisfactorily alleviate the discomforts of the disease even during
treatment and the products themselves are often messy and
unpleasant to apply. Likewise, there have been very few treatments
for psoriasis over the years but positive responses to treatment
have been rarely found. Commonly, stiff, occlusive preparations
which increase the hydration of dry, scaly skin have been used.
These are often painful to apply and the preparation is messy
usually leaving the patient discouraged. Also, current treatments
of atopic dermatitis (eczema) have provided little beneficial
effects or the drugs used (corticosteroids) have a high incidence
of adverse side-effects. Treatment has often relied upon the
properties of the pharmaceutical base to alter the extent of
hydration of the skin.
Applicant is aware of a preparation sold under the trade mark
"Blistex" used to treat cold sores. Applicant believes this product
is petrolatum based. Applicant is also aware of a product bearing
the trade mark "Listerine" used as a mouth wash and which Applicant
believes comprises eucalyptol, menthol and thymol.
As a result of conducting a patent search, Applicant has become
aware of
(a) U.S. Pat. Nos. 4,262,007 and 4,390,539 which relate to a method
for treating viral skin diseases including the use of benzethonium
chloride;
(b) U.S. Pat. No. 4,130,638 which relates to a mouth wash
containing alcohol and a flavouring agent selected from the group
consisting of menthol, thymol, eucalyptol and anethol or mixtures
thereof with peppermint oil;
(c) U.S. Pat. No. 3,408,298 which relates to a detergent germicidal
composition comprising alkyl dimethyl benzyl ammonium chloride;
(d) U.S. Pat. No. 4,574,081 relating to an antiplaque dentifrice
comprising an antiplaque quaternary ammonium compound, a flavouring
agent comprising anethol and menthol;
(e) Canadian Letters Patent 899235 relating to a skin disinfectant
composition comprising an aqueous solution of a complex of iodine
with a mixture of alkyl dimethyl dichlorobenzyl ammonium chlorides
in which the alkyl substituents contain 12 and 18 carbon atoms;
(f) U.S. Pat. No. 4,678,598 relating to a liquid shampoo comprising
at least one surface active agent and a skin sensation inducing
aromatic chemical selected from a group comprising among other
chemicals menthol and cineol (which Applicant believes is another
name for eucalyptol);
(g) Canadian Letters Patent 739927 relating to a thixotopic
composition for treating skin maladies comprising alcohol and
menthol;
(h) U.S. Pat. No. 4,702,916 relating to an analgesic stick
comprising menthol;
(i) U.S. Pat. No. 4,669,491 at column 11, lines 39-46 relating to a
biocide comprising at least one of
5-methyl-2-isopropyl-cyclohexanol, cineole and thymol amongst other
chemicals;
(j) European Patent Application 86200131.0 relating to a method of
killing viruses like Herpes virus Type I and Type II by contacting
them with a viricidal composition comprising benzethonium chloride,
ethanol, water, and a flavouring agent; and,
(k) Romanian Reference 77453 relating to a medicament containing
iodine.
According to the present invention there are provided novel
compositions of matter for the treatment of dermal disease
including labial, nasal, and genital lesions caused by Herpes
Simplex, acne, psoriasis, and dermatitis. The novel pharmaceutical
compositions comprise a combination of common medicinal agents,
believed to act synergistically, one with the other, which exert a
healing and a pain-relieving action. A solvent of acetone and water
is preferred, believed to play a role in the effectiveness of the
preparation but it is not considered essential to the overall
synergistic action of the present invention.
The treatment of the skin diseases known as cold sores, fever
blisters, genital herpes, psoriasis, acne, or eczema and the like
using embodiments of the invention may be explained in part (in
addition to the synergistic effect of combining the components)
based on a completely different rationale than that which is
currently practised. The inventor offers this explanation which
should not be considered determinative of the operation of the
formulations. It is offered solely to give the reader some insight
of the inventors' consideration. Current modes of treatment are
generally based on the application of medicament in a cream or
ointment base having the properties of softening and lubricating
the skin in the affected areas or promoting increased hydration of
the stratum corneum layer of the epidermis. Although this often has
the benefit of short-term relief of the discomfort and pain or
itching from the diseased skin condition, this principle of
treatment does not usually facilitate penetration of the
medicament(s) into the skin or promote pharmacological action. In
contrast, it is believed that application of the embodiments of the
present invention immediately modify the dried keratin layer of the
epidermis to enable rapid penetration of the antiseptic,
anesthetic, and antipruritic agents as the case may be into the
skin for relief of pain, itching, and the destruction of viral and
bacterial cells which are the source of the diseased skin
condition. In the case of psoriasis or certain types of eczema,
embodiments of the present invention cause rapid sloughing off of
the excess stratum corneum characteristic of these diseases,
without the discomfort of inunction or the unpleasantness of a
greasy layer on the skin. Consequently, the rapid return to a
normal, healthy skin condition is obtained. It is because of this
new approach to the treatment of these skin diseases that it is
believed that the successes with volunteer subjects described in
the examples have been obtained.
Formulations according to the present invention may also be
formulated with other substances, for example, excipients, and may
be in one of several galenical forms including a gel, a cream, a
lotion, an ointment, or a paste, at various concentrations as
necessary to exert the optimum effectiveness.
It is also believed that the present invention is effective in the
manner described by combining at least three of the stated
ingredients in a solution, for example of acetone and water or
other aqueous solvent system.
Application of formulations according to the present invention to
Herpes labialis (cold sores) in some cases stopped the cycle at one
eruption, caused progression to the scab stage almost immediately,
and the complete cycle was reduced to only a few days. Application
to Herpes genitalis at the earliest stage in some cases resulted in
only one eruption, the scab stage was begun immediately, and the
cycle time was drastically reduced. Application to acne lesions in
some cases caused them to vanish within hours and those in the
prodromal stage aborted within 24 hours. Application to psoriasis
in some cases removed the accumulation of corneal epidermis,
alleviated pain, promoted healing, and its continued use eliminated
any further accumulation of epidermal layers. One application of
the present invention to atopic dermatitis (eczema) resulted in
successful treatment whereas other modalities of treatment were
less effective.
According to one aspect of the invention a preparation is provided
which is compatible with the skin for the treatment of dermatologic
diseases, for example labial, nasal and genital lesions caused by
Herpes Simplex, acne, psoriasis and dermatitis the preparation
comprising a mixture of
(a) at least one antiseptic and/or anesthetic compound which is
(i) a terpene (e.g. menthol and eucalyptol);
(ii) a phenolic compound (e.g. thymol); or,
(iii) an alcohol;
(b) a quaternary ammonium antiseptic compound;
(c) an antiseptic compound containing iodine, salts thereof and/or
complexes thereof dissolved in an organic skin penetrating
solvent.
According to another aspect of the invention, a method of treating
dermatologic diseases (for example labial, nasal and genital
lesions caused by Herpes Simplex, acne, psoriasis and dermatitis)
is provided comprising administering an effective amount of a
preparation compatible with the skin comprising a mixture of
(a) at least one antiseptic and/or anesthetic compound which is
(i) a terpene (e.g. menthol and eucalyptol);
(ii) a phenolic compound (e.g. thymol); or,
(iii) an alcohol;
(b) a quaternary ammonium antiseptic compound;
(c) an antiseptic compound containing iodine, salts thereof and/or
complexes thereof dissolved in an organic skin penetrating
solvent.
In one embodiment the selected antiseptic and/or anesthetic
compound is a terpene and preferably the terpene is an oxygenated
terpene. In another embodiment the quaternary ammonium antiseptic
compound is benzethonium chloride. In another embodiment the
antiseptic and/or anesthetic compound is a phenolic compound and
the phenolic compound is thymol. In another embodiment the
oxygenated terpene is selected from eucalyptol and menthol (which
may also be considered an alcohol). In still another embodiment the
oxygenated terpene comprises a mixture of eucalyptol and menthol.
In still another embodiment the at least one antiseptic and/or
anesthetic compound comprises a mixture of at least one phenolic
compound and at least one terpene. Preferably the organic skin
penetrating solvent is a mixture of acetone and water. In one
embodiment at least one phenolic compound or at least one terpene
comprises a mixture of eucalyptol, menthol and thymol. In this
embodiment the quaternary ammonium antiseptic compound may be
benzethonium chloride, the antiseptic compound containing iodine,
salts thereof or complexes thereof comprises iodine and potassium
iodide and the organic skin penetrating solvent is a mixture of
acetone and water.
One embodiment of the present invention may comprise a solution of
menthol, thymol, eucalyptol, potassium iodide, iodine, and
benzethonium chloride in acetone:water or other aqueous solvent
system. This, and other combinations of medicinal agents referred
to above, all of which are presently commercially available, are
effective treatments of the dermatologic skin disorders commonly
referred to as cold sores, fever blisters, genital Herpes,
psoriasis, eczema, and acne. The mechanisms of these actions are
unknown but a response to treatment using the combinations has been
observed to be markedly different than any of the individual
component agents comprising the present invention. For instance,
the antibacterial and bactericidal effects of potassium iodide,
iodine, and benzethonium chloride are well known and they occur in
many commercial products. However, combinations of these agents
have not previously been employed in the particular manner
described herein to treat the diseased skin disorders previously
cited. Surprisingly, there are few topical skin treatments
presently available, other than the present invention, which
satisfactorily alleviate the pain, itching, and sensitivity of the
skin to occurrences of the lesions of Herpes, the eruptions of
acne, the dry, scaly condition of psoriasis, or the apparent rashed
condition of eczema.
Typical amounts of the various components may include the
following:
(a) the at least one antiseptic and/or anesthetic compound may be
in a range of about 0.02%--about 2% by weight of the
preparation;
(b) the quaternary ammonium antiseptic compound may be in the range
of about 0.05%--about 3% by weight of the preparation;
(c) the antiseptic compound containing iodine, salts thereof and/or
complexes thereof may be in the range of about 0.02%--about 2% by
weight of the preparation.
The organic skin penetrating solvent may be in the range exceeding
about 50%. The at least one antiseptic and/or anesthetic compound
may comprise eugenol, camphor, hexetidine or anethol or the like.
The organic skin penetrating solvent may comprise Dimethyl
Sulfoxide (DMSO), azone, propylene glycol, dimethyl formamide,
dimethyl acetamide, ethyl or isopropyl alcohol or the like in
water. The quaternary ammonium antiseptic compound may be
benzalkonium chloride, cetyl trimethylammonium bromide (CTAB) and
cetyl pyridium chloride or the like.
As illustrated in the following examples, it is believed that the
combination of ingredients act synergistically to produce the
beneficial treatments observed.
EXAMPLE 1
A typical recipe of the synergistic combination of medicinal agents
is as follows:
______________________________________ Menthol 1.25 g Thymol 0.25 g
Eucalyptol 0.03 g Potassium iodide 0.03 g Iodine 0.03 g
Benzethonium chloride 0.20 g Acetone:water(70:30) qs 60 ml
______________________________________
The effectiveness of the present invention has been tested on
volunteer patients. A full-scale clinical study has not yet been
undertaken.
Directions (Treatment for Herpes Simplex I and II)
1. Apply liberally to the afflicted area 3 to 4 times over a one
minute time period. Repeat every 3 minutes over a 10 minute
period.
2. Repeat above procedure after approximately 1/2 to 1 hour.
3. To ensure virus activity is stopped repeat application as
prescribed in initial treatment every 2 to 3 hours or until
activity is stopped and healing is evident.
4. To hasten healing apply 2 to 3 applications twice daily.
NOTE: If applied at the early prodromal stage (when a tingling
sensation is first noticed) no blistering is evident.
For prodromal stage treatments use as prescribed in 1, 2 and 3.
EXAMPLE 2
Treatment of Herpes Simplex I (Herpes labialis)
No. of patients: approx. 12
The recipe according to Example 1 was prepared by dissolving and
mixing the ingredients in a vehicle of acetone:water. Each patient
was directed to apply the liquid directly to the cold sore using a
cotton swab or other type of applicator. Optimum results were
obtained when the preparation was applied liberally on the
blistered area, the application repeated three times over a 10 min
period, then repeated for three consecutive hours. Excellent
results were also obtained when the treatment was applied twice a
day for one day. The patients reported a very positive response to
this treatment indicating an awareness of its immediate healing
action. The cold sore quickly progressed to the scab stage and the
lesion disappeared. No further eruptions occurred.
Each patient claimed that no other product was nearly as
effective.
EXAMPLE 3
Treatment of Herpes Simplex II (Herpes genitalis)
No. of patients: 7
Each patient was directed to apply the liquid according to Example
1 to the eruptions in the same manner as described in Example 2.
Again, the results were immediate. When applied at full cycle,
drying of the eruptions occurred quickly and then progressed to the
scab stage. If applied at the prodromal stage, so blistering was
evident or only one eruption appeared and the cycle appeared
stopped. Again, the patients reported that this treatment was far
superior to any other products known to them. No side effects to
this treatment were reported. Furthermore, earlier treatment
diminished or eliminated the skin blemishes which are
characteristic of the usual Herpes outbreak.
EXAMPLE 4
Treatment of Acne
No. of patients: 12
Each patient was directed to apply the liquid of Example 1 to open
or closed comedos for 1 min, to repeat the application three times
over a 10 min period, and to repeat the treatment after 2 hr. The
results of the applications were pain relief immediately and
reduction in size of the eruptions followed by complete
disappearance within 2 to 3 days. When the medication was used in
the prodromal stage, the comedos were abortive.
EXAMPLE 5
Treatment of Psoriasis
No. of patients: 3 (1 female, 2 males)
Each patient applied the liquid of Example 1 to red, dry, scaly
epidermal skin for 2 min in the morning and again in the
evening.
Directions (Treatment for Psoriasis)
1. Apply liberally to the afflicted area 3 to 4 times over a one
minute time period. Repeat every 3 minutes over a 10 minute
period.
2. The procedure is preferably carried out in the mornings.
3. This procedure is repeated after approximately 1/2 to 1 hour
before going to bed.
A female patient proceeded with normal daily activities with her
legs covered by nylon stockings. At the end of the day considerable
sloughing of the corneal layer had occurred and this was easily
washed off. A second application on the following day under the
same conditions produced similar results but at this point the
excess dead epidermal cells had essentially been removed and the
skin was smooth and supple like normal skin. No particular
discomfort or sensitivity was experienced during or following this
treatment. Repeated treatments from time to time ensured that the
symptoms of psoriasis did not reoccur. Patients reported this
treatment to be far superior to any previous treatment practised
with over-the-counter products or under the care of a
physician.
It should be noted that over-use of this preparation after the
build-up of skin has been eliminated may cause a drying effect. To
eliminate drying and cracking of the tender pink skin the frequency
of application of the preparation should be reduced and a skin
moisturizing lotion (baby oil) applied.
EXAMPLE 6
Treatment of Atopic Dermatitis (Eczema)
No. of patients: 2
Generally, treatments of eczema using presently available
commercial products serve to alleviate the symptoms of itching,
soreness, and sensitivity to varying degrees. However, using the
liquid preparation of Example 1 applied liberally on the infected
area for 1 min, then repeated in 10 min caused the discrete wheals
characteristic of this disease to soon disappear and the skin to
return to its normal colour and texture. The patients reported that
this treatment was more effective than any previous treatment
attempted.
It is apparent that the beneficial therapeutic effects experienced
by this limited number of volunteer patients are due to a
synergistic action of the particular combination of medicinal
agents described in the present invention. Although the present
invention as described in Example 1 was accepted in that form by
the patients, it is further apparent that for some applications
certain types of galenical forms could increase the acceptance of
this treatment of sensitive, visible parts of the anatomy.
As many changes can be made to the embodiment without departing
from the scope of the invention, it is intended that all material
contained herein be interpreted as illustrative of the invention
and not in a limiting sense.
* * * * *